Evidence map›Paper›PMID 28396914›Full record

ReviewDer Internist2017

[Anticoagulation in patients with chronic kidney disease : Recommendations from the working group "Heart-Kidney" of the German Cardiac Society and the German Society of Nephrology].

G Schlieper, V Schwenger, A Remppis, T Keller, R Dechend, S Massberg, S Baldus, T Weinreich, G Hetzel, J Floege and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Internist, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Biased Results Owing to Competing Interests?Deutsches Arzteblatt international · 2018
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 2 countries.

G SchlieperMVZ DaVita Rhein-Ruhr, Bismarckstr. 101, 40210, Düsseldorf, Deutschland. georg.schlieper@davita-dialyse.de.
V SchwengerKlinik für Nieren- und Hochdruckkrankheiten, Transplantationszentrum, Klinikum Stuttgart, Stuttgart, Deutschland.
A RemppisKlinik für Kardiologie, Pneumologie und kardiorenale Medizin, Herz- und Gefäßzentrum, Bad Bevensen, Deutschland.
T KellerMedizinische Klinik III: Kardiologie, Angiologie, Nephrologie, Universitätsklinikum Frankfurt, Frankfurt, Deutschland.
R DechendHELIOS Klinikum Berlin-Buch und Experimental and Clinical Research Center, Charité - Campus Buch, Berlin, Deutschland.
S MassbergMedizinische Klinik und Poliklinik I, Klinikum der Universität München, München, Deutschland.
S BaldusKlinik III für Kardiologie, Angiologie, Pneumologie und Internistische Intensivmedizin, Herzzentrum der Universität zu Köln, Köln, Deutschland.
T WeinreichNephrologisches Zentrum Villingen-Schwenningen, Villingen-Schwenningen, Deutschland.
G HetzelMVZ DaVita Rhein-Ruhr, Bismarckstr. 101, 40210, Düsseldorf, Deutschland.
J FloegeMedizinische Klinik II, Klinik für Nieren- und Hochdruckkrankheiten, Rheumatologische und Immunologische Erkrankungen, Uniklinik RWTH Aachen, Aachen, Deutschland.
F MahfoudKlinik für Innere Medizin III - Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar, Deutschland.
D FliserKlink für Innere Medizin IV - Nieren- und Hochdruckkrankheiten, Universitätsklinikum des Saarlandes, Homburg/Saar, Deutschland.
Universitätsklinikum des Saarlandes · DECharité - Universitätsmedizin Berlin · DEKlinik Lüneburger Heide · DEKlinikum Stuttgart · DELMU Klinikum · DENephrologisches Zentrum Villingen-Schwenningen · DEUniversitätsklinikum Aachen · DEUniversity Hospital Frankfurt · DEUniversity of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Indications for anticoagulation are thromboembolic events, prosthetic heart valves, and atrial fibrillation with a corresponding risk score. Clinical trials have excluded patients with advanced chronic kidney disease and these data cannot be always generalized to patients with chronic kidney disease. Non-vitamin K antagonist oral anticoagulants (NOACs) are mostly not recommended or are contraindicated in advanced stages of chronic kidney disease. Observational studies have shown that dialysis patients with atrial fibrillation do not profit from coumarin anticoagulants; prospective studies are lacking.

Indexed as

Renal Insufficiency, ChronicAnticoagulantsAtrial FibrillationContraindications, DrugCoumarinsGermanyHumansNephrologyProspective StudiesSocieties, MedicalStrokeAnticoagulantscoumarinCoumarinsAnticoagulantsAtrial fibrillationPhenprocoumonRenal diseaseWarfarin

Identifiers

PMID28396914
OpenAlexW2607277152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.